ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 0224 • ACR Convergence 2024

    How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries

    Anna EF Hadsbjerg1, Simon Krabbe2, Nora Vladimirova2, Adrian Ciurea3, Kristyna Bubova4, Monika Gregová4, Michael Nissen5, Burkhard Moeller6, Raphael Micheroli7, Susanne Pedersen8, Jakub Zavada4, Ziga Snoj9, Karlo Pintaric9, Bjorn Gudbjornsson10, Ziga Rotar11, iris Eshed12, Iwona Sudol-Szopinska13, Kasper Gosvig14, Torsten Diekhoff15, Robert Lambert16, Manouk de hOoge17, Helena V G Elmo1, Merete Hetland18, Lykke Oernbjerg19 and Mikkel Ostergaard20, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Righospitalet, Copenhagen, Denmark, 3University Hospital Zurich, Zürich, Switzerland, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, 5Geneva University Hospital, Geneva, Switzerland, 6Inselspital - University Hospital Bern, Bern, Switzerland, 7University Hospital Zurich, Zurich, Switzerland, 8Rigshospitalet, København, Denmark, 9Institute of Radiology, UMC Ljubljana, Ljubljana, Slovenia, 10Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 11University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 12Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, 13Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, 14Department of Radiology, Copenhagen University Hospital Herlev-Gentofte, Herlev, Denmark, 15Charite Universitatsmedizin Berlin, Berlin, Germany, 16University of Alberta, Edmonton, AB, Canada, 17Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 18Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 19Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 20Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark

    Background/Purpose: MRI of the sacroiliac joints (SIJs) is widely used for diagnosing and monitoring patients with spondyloarthritis (SpA). However, local radiologists might be less familiar with…
  • Abstract Number: 0586 • ACR Convergence 2024

    Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry

    Alexis Ogdie1, Xiaolan Ye2, Yi Peng3, Christopher Saffore4, Jayne Stigler5 and Martin Bergman6, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2AbbVie Inc., Mettawa, IL, 3AbbVie Inc, North Chicago, IL, 4AbbVie Inc., waukegan, IL, 5AbbVie Inc., North Chicago, IL, 6self, Beach Haven, NJ

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
  • Abstract Number: 0851 • ACR Convergence 2024

    Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site

    Lihi Eder1, Ricardo Acayaba de Toledo2, Fahmeen Afgani3, Catherine Bakewell4, Philippe Carron5, Basant Elnady6, Amir Haddad7, Arthur Kavanaugh8, Arnon Katz9, Minna Kohler10, josefina marin11, NZEUSSEU TOUKAP Adrien12, Marcos Rosemffet13, Ari Polachek14, Ernesto Rodriguez15, Ágnes Sarolta Szentpétery16, Abha Singh17, Maria S. Stoenoiu18, Ilaria Tinazzi19, Janeth Yinh10, Gurjit Kaeley20 and Sibel Aydin21, 1University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 2FAMERP, São José do Rio Preto, Brazil, 3Women's College Hospital, Toronto, Canada, 4Intermountain Health Care, Salt Lake City, UT, 5UZ Gent, Gent, Belgium, 6Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, 7Carmel Medical Centre, Haifa, Israel, 8University of California San Diego, La Jolla, CA, 9GRAPPA - Patient Research Partner, Haifa, Israel, 10Massachusetts General Hospital, Boston, MA, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 13Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 14Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 15Florida Medical Clinic, Tampa, FL, 16Uppsala University Hospital, Uppsala, Sweden, 17University of California, San Diego, San Diego, CA, 18Cliniques Universitaires Saint-Luc, Brussels, Belgium, 19Ospedale Sacro Cuore-Don Calabria, Verona, Italy, 20UF COM-J, Ponte Vedra Beach, FL, 21University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…
  • Abstract Number: 1249 • ACR Convergence 2024

    Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

    Shilpa Venkatachalam1, Kelly Gavigan2, Erik Stone3, Angela Degrassi2, Laura Stradford4, David Curtis2, Esteban Rivera5 and Jeffrey Curtis6, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Long Island City, NY, 6University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
  • Abstract Number: 1465 • ACR Convergence 2024

    The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial

    Laure Gossec1, Laura Coates2, Dafna Gladman3, Alexis Ogdie4, Peter Nash5, Denis Poddubnyy6, Arthur Kavanaugh7, April Armstrong8, Carlo Selmi9, Ruben Queiro Silva10, Cynthia Deignan11, Rebecca Wang11, Jyotsna Reddy11, Michele Brunori11 and Philip Mease12, 1Sorbonne Université, Paris, France, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 6Charite-Universitatsmedizin Berlin, Berlin, Germany, 7University of California, San Diego, School of Medicine, La Jolla, CA, 8University of California Los Angeles, Los Angeles, CA, 9Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, 10Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, 11Amgen Inc., Thousand Oaks, CA, 12Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Oligoarticular psoriatic arthritis (PsA, ≤4 joints affected) is common but understudied, as most clinical trials enroll patients (pts) with ≥3 swollen and tender joints.…
  • Abstract Number: 1883 • ACR Convergence 2024

    Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review

    Batoul Hojeij1, Gonul Hazal Koc2, Jolanda Luime1, Marijn Vis1, Marc R. Kok3 and Ilja Tchetverikov4, 1Erasmus MC, Rotterdam, Netherlands, 2Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4Albert Schweitzer Hospital, Dordrecht, Netherlands

    Background/Purpose: Combined assessment of psoriatic arthritis (PsA) flare incidence and risk factors has not been conducted before, leading to challenges in effective flare management, especially…
  • Abstract Number: 2314 • ACR Convergence 2024

    Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort

    Alla Ishchenko1, Margot Van Mechelen2, Sofia Pazmino3, Lies Storms4, Patrick Verschueren5, Rik Lories6 and Kurt de Vlam7, 1UZ Gasthuisberg, Leuven, Belgium, 2Antwerp University Hospital, Belgium, Antwerp, Belgium, 3KU Leuven University, Leuven, Belgium, Leuven, Belgium, 4KU Leuven, Leuven, Belgium, 5Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, 6Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, 7Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium

    Background/Purpose: Systemic inflammation is an integral part of psoriatic arthritis (PsA). Despite substantial inflammation in the affected tissues such as skin, entheses and joints, C-reactive…
  • Abstract Number: 2331 • ACR Convergence 2024

    Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course

    Dafne Capelusnik1, Ori Elkayam2 and Mark Berman3, 1Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Kefar sava, Israel

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can cause joint pain, swelling, and stiffness. Patients often experience flares followed by periods of remission.…
  • Abstract Number: 2351 • ACR Convergence 2024

    Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials

    Irene E. van der Horst-Bruinsma1, Matthew A. Brown2, Floris van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10 and Martin Rudwaleit11, 1Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 2Genomics England, London, United Kingdom, 3LUMC, Leiden, Zuid-Holland, Netherlands, 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Braine-l'Alleud, Belgium, 8UCB Pharma, Atlanta, GA, 9UCB Pharma, Slough, United Kingdom, 10Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 11University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany

    Background/Purpose: Acute anterior uveitis (‘uveitis’) is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA), and incidence varies with SpA type and disease duration.1,2,3…
  • Abstract Number: 2584 • ACR Convergence 2024

    Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial

    Philip Mease1, Alan Kivitz2, Elena Muensterman3, Apinya Lertratanakul4, Ting Hong4, Jingjing Chen4, Ejim Mark5 and Xenofon Baraliakos6, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Altoona Center for Clinical Research, Duncansville, PA, 3Takeda Development Center Americas, Cambridge, MA, 4Takeda Development Center Americas, Inc., Cambridge, MA, 5Takeda Development Center Americas Inc., Cambridge, 6Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase…
  • Abstract Number: 0225 • ACR Convergence 2024

    Prediction of Response to Therapies and Flares Based on Ultrasound Findings at Baseline in Psoriatic Arthritis: An Analysis on a Joint Level

    Ummugulsum Gazel1, Seyyid Bilal Acikgoz2, Ricardo Sabido-Sauri1, Ozun Bayindir Tsechelidis3, Sylvia Sangwa4, Elliot Hepworth1 and Sibel Aydin5, 1University of Ottawa, Ottawa, ON, Canada, 2University of Ottawa, Rheumatology, Ottawa, ON, Canada, 3Ottawa University, Ottawa, ON, Canada, 4The Ottawa Hospital Research Institute, Ottawa, Canada, 5University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: It is not clear how to interpret when the ultrasound and physical examination do not agree on a joint level. In this study, we…
  • Abstract Number: 0587 • ACR Convergence 2024

    Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab

    William Tillett1, Dafna Gladman2, Laure Gossec3, Jason Eells4, Patrick Healy5, Barbara Ink4, Nikos Lyris4 and Jessica A Walsh6, 1Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Sorbonne Université, Paris, France, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Morrisville, NC, 6Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT

    Background/Purpose: Psoriatic arthritis (PsA) negatively impacts patients’ physical health and functional ability, which can contribute to reduced work productivity.1,2 We examined the association between achieving…
  • Abstract Number: 0928 • ACR Convergence 2024

    In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects

    monia Maccaferri1, Francesco Zambianchi2, Carlo Salvarani3 and Elisa Pignatti3, 1Azienda Ospedaliero Universitaria di Modena, Modena, Italy, 2Department of Maternal, Child and Adult Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy, 3Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

    Background/Purpose: Interactions between fibroblast-like synoviocytes (FLSs) and macrophage-like synoviocytes (MLSs) are pivotal in the pathogenesis of RA and PsA. FLSs both activate and are activated…
  • Abstract Number: 1296 • ACR Convergence 2024

    Effectiveness of Inflammatory Arthritides Educational Modules and Potential for Improved Referral Times

    Christine Kim1, Vincent Vertalino2, Karen Kruzer3 and Allen Anandarajah4, 1University of Rochester, Rochester, 2University of Rochester, Hamburg, NY, 3University of Rochester, Victor, NY, 4University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Early diagnosis and treatment of inflammatory arthritides [rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)] are associated with improved patient outcomes. However,…
  • Abstract Number: 1466 • ACR Convergence 2024

    Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial

    Laure Gossec1, Laura Coates2, Dafna Gladman3, Alexis Ogdie4, Alvin F. Wells5, Joseph Merola6, Paolo Gisondi7, andreas pinter8, Mitsumasa Kishimoto9, Jyotsna Reddy10, Hamid Amouzadeh10, Rebecca Wang10, Shauna Jardon10, Michele Brunori10 and Philip Mease11, 1Sorbonne Université, Paris, France, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Rheumatology and Immunotherapy Center, Franklin, WI, 6UT Southwestern Medical Center, Newton, MA, 7Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, 8University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, 9Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 10Amgen Inc., Thousand Oaks, CA, 11Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Most clinical trials of Psoriatic Arthritis (PsA) exclude patients with early oligoarticular (oligo) disease and there is limited evidence to drive treatment decisions in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology